Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015 (2015), Article ID 468574, 12 pages
http://dx.doi.org/10.1155/2015/468574
Research Article

Protective Effects of Paricalcitol on Peritoneal Remodeling during Peritoneal Dialysis

1Department of Molecular Cell Biology & Immunology, VU University Medical Center, 1081 BT Amsterdam, Netherlands
2Department of Nephrology, VU University Medical Center, 1007 MB Amsterdam, Netherlands
3Institute for Cardiovascular Research VU (ICaR-VU), VU University Medical Center, 1007 MB Amsterdam, Netherlands

Received 15 May 2015; Revised 10 September 2015; Accepted 1 October 2015

Academic Editor: Gernot Zissel

Copyright © 2015 Andrea W. D. Stavenuiter et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. D. Williams, K. J. Craig, N. Topley et al., “Morphologic changes in the peritoneal membrane of patients with renal disease,” Journal of the American Society of Nephrology, vol. 13, no. 2, pp. 470–479, 2002. View at Google Scholar · View at Scopus
  2. P. K.-T. Li, C. C. Szeto, B. Piraino et al., “Peritoneal dialysis-related infections recommendations: 2010 update,” Peritoneal Dialysis International, vol. 30, no. 4, pp. 393–423, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. E. Baroni, M. Biffi, F. Benigni et al., “VDR-dependent regulation of mast cell maturation mediated by 1,25-dihydroxyvitamin D3,” Journal of Leukocyte Biology, vol. 81, no. 1, pp. 250–262, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. A. S. Dusso, A. J. Brown, and E. Slatopolsky, “Vitamin D,” American Journal of Physiology: Renal Physiology, vol. 289, no. 1, pp. F8–F28, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. A. S. Dusso, “Kidney disease and vitamin D levels: 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and VDR activation,” Kidney International Supplements, vol. 1, pp. 136–141, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. L. H. Hekking, M. C. Aalders, E. van Gelderop et al., “Effect of peritoneal dialysis fluid measured in vivo in a rat-model of continuous peritoneal dialysis,” Advances in Peritoneal Dialysis, vol. 14, pp. 14–18, 1998. View at Google Scholar · View at Scopus
  7. A. J. Fosang, N. J. Hey, S. L. Carney, and T. E. Hardingham, “An Elisa plate based assay for hyaluronan using biotinylated proteoglycan G1 domain (HA-binding region),” Matrix, vol. 10, no. 5, pp. 306–313, 1990. View at Publisher · View at Google Scholar · View at Scopus
  8. M. N. Schilte, J. Loureiro, E. D. Keuming et al., “Long-term intervention with heparins in a rat model of peritoneal dialysis,” Peritoneal Dialysis International, vol. 29, no. 1, pp. 26–35, 2009. View at Google Scholar · View at Scopus
  9. F. K. Li, “Effect of peritoneal dialysis on peritoneal macrophages,” Peritoneal Dialysis International, vol. 19, supplement 2, pp. S343–S347, 1999. View at Google Scholar · View at Scopus
  10. P. Fabbrini, M. N. Schilte, M. Zareie et al., “Celecoxib treatment reduces peritoneal fibrosis and angiogenesis and prevents ultrafiltration failure in experimental peritoneal dialysis,” Nephrology Dialysis Transplantation, vol. 24, no. 12, pp. 3669–3676, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. F. Takahashi, J. L. Finch, M. Denda, A. S. Dusso, A. J. Brown, and E. Slatopolsky, “A new analog of 1,25-(OH)2D3, 19-NOR-1,25-(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content,” American Journal of Kidney Diseases, vol. 30, no. 1, pp. 105–112, 1997. View at Publisher · View at Google Scholar · View at Scopus
  12. I. H. de Boer, M. Sachs, A. N. Hoofnagle et al., “Paricalcitol does not improve glucose metabolism in patients with stage 3-4 chronic kidney disease,” Kidney International, vol. 83, no. 2, pp. 323–330, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. X. Y. Tan, Y. J. Li, and Y. H. Liu, “Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy,” Journal of the American Society of Nephrology, vol. 17, no. 12, pp. 3382–3393, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. Y. Zhang, J. Kong, D. K. Deb, A. Chang, and Y. C. Li, “Vitamin D receptor attenuates renal fibrosis by suppressing the renin-angiotensin system,” Journal of the American Society of Nephrology, vol. 21, no. 6, pp. 966–973, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. D. L. Andress, “Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation,” Kidney International, vol. 69, no. 1, pp. 33–43, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Freundlich, Y. Quiroz, Z. Zhang et al., “Suppression of renin-angiotensin gene expression in the kidney by paricalcitol,” Kidney International, vol. 74, no. 11, pp. 1394–1402, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. G. T. González-Mateo, V. Fernández-Míllara, T. Bellón et al., “Paricalcitol reduces peritoneal fibrosis in mice through the activation of regulatory T Cells and reduction in IL-17 production,” PLoS ONE, vol. 9, no. 10, Article ID e108477, 2014. View at Publisher · View at Google Scholar
  18. N. Higashi-Kuwata, T. Makino, Y. Inoue, M. Takeya, and H. Ihn, “Alternatively activated macrophages (M2 macrophages) in the skin of patient with localized scleroderma,” Experimental Dermatology, vol. 18, no. 8, pp. 727–729, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. D. V. Pechkovsky, A. Prasse, F. Kollert et al., “Alternatively activated alveolar macrophages in pulmonary fibrosis-mediator production and intracellular signal transduction,” Clinical Immunology, vol. 137, no. 1, pp. 89–101, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. H.-J. Anders and M. Ryu, “Renal microenvironments and macrophage phenotypes determine progression or resolution of renal inflammation and fibrosis,” Kidney International, vol. 80, no. 9, pp. 915–925, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. T. T. Braga, M. Correa-Costa, Y. F. S. Guise et al., “MyD88 signaling pathway is involved in renal fibrosis by favoring a TH2 immune response and activating alternative M2 macrophages,” Molecular Medicine, vol. 18, no. 8, pp. 1231–1239, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. T. Bellón, V. Martínez, B. Lucendo et al., “Alternative activation of macrophages in human peritoneum: implications for peritoneal fibrosis,” Nephrology Dialysis Transplantation, vol. 26, no. 9, pp. 2995–3005, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Wang, Z.-P. Jiang, N. Su et al., “The role of peritoneal alternatively activated macrophages in the process of peritoneal fibrosis related to peritoneal dialysis,” International Journal of Molecular Sciences, vol. 14, no. 5, pp. 10369–10382, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. D. Y. S. Vogel, J. E. Glim, A. W. D. Stavenuiter et al., “Human macrophage polarization in vitro: maturation and activation methods compared,” Immunobiology, vol. 219, no. 9, pp. 695–703, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. T. Oikawa, K. Hirotani, H. Ogasawara et al., “Inhibition of angiogenesis by vitamin D3 analogues,” European Journal of Pharmacology, vol. 178, no. 2, pp. 247–250, 1990. View at Publisher · View at Google Scholar · View at Scopus
  26. D. Zehnder, R. Bland, R. S. Chana et al., “Synthesis of 1,25-dihydroxyvitamin D3 by human endothelial cells is regulated by inflammatory cytokines: a novel autocrine determinant of vascular cell adhesion,” Journal of the American Society of Nephrology, vol. 13, no. 3, pp. 621–629, 2002. View at Google Scholar · View at Scopus
  27. A. W. D. Stavenuiter, M. N. Schilte, P. M. ter Wee, and R. H. J. Beelen, “Angiogenesis in peritoneal dialysis,” Kidney and Blood Pressure Research, vol. 34, no. 4, pp. 245–252, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. J. Niu, A. Azfer, O. Zhelyabovska, S. Fatma, and P. E. Kolattukudy, “Monocyte chemotactic protein (MCP)-1 promotes angiogenesis via a novel transcription factor, MCP-1-induced protein (MCPIP),” The Journal of Biological Chemistry, vol. 283, no. 21, pp. 14542–14551, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Zareie, E. D. Keuning, P. M. ter Wee, C. G. Schalkwijk, R. H. J. Beelen, and J. van den Born, “Improved biocompatibility of bicarbonate/lactate-buffered PDF is not related to pH,” Nephrology Dialysis Transplantation, vol. 21, no. 1, pp. 208–216, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. S. H. Kang, S. O. Kim, K. H. Cho, J. W. Park, K. W. Yoon, and J. Y. Do, “Paricalcitol ameliorates epithelial-to-mesenchymal transition in the peritoneal mesothelium,” Nephron: Experimental Nephrology, vol. 126, no. 1, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. X. Tan, Y. Li, and Y. Liu, “Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy,” Journal of the American Society of Nephrology, vol. 17, no. 12, pp. 3382–3393, 2006. View at Publisher · View at Google Scholar · View at Scopus